2869

## REMARKS

The Applicants object to the Examiner's withdrawal of claims 2, 4-6, 9-13, 15-16, and 25-27 on the basis of there being no allowable generic or making claim.

The Applicants respectfully point out that there is only one independent claim, namely claim 1, which, if allowable, is linked to each and every one of the dependent claims including claims 2, 4-6, 9-13, 15-16, and 25-27. Withdrawal of these claims would require redundant addition of these claims depending upon the allowability of claim 1.

Accordingly, the Applicants respectfully request the Examiner do not withdraw claims 2, 4-6, 9-13, 15-16, and 25-27 but rather consider them as dependent claims.

The Examiner has also objected to the listing of the references in the specification is not a proper Information Disclosure Statement.

The Applicants submit that each of the references cited in the Application are also listed on the Information Disclosure Statement by the Applicant and signed by the Examiner, copy enclosed.

Thus, the Applicants request consideration thereof by the Examiner.

The Examiner has rejected claims 1, 3, 19, and 21-24 as being anticipated by U.S. 4,366,169 to White. In this rejection, the Examiner states that White teaches a substrate

and oxygen carrier wherein the carrier comprises a fluorocarbon compositions which are lipophilic of various polymeric compositions.

The Applicants submit that anticipation is established only when a single prior art reference discloses, expressly or under principles of inherency, each and every element of the claimed invention. RCA Corp. v. Applied Digital Data Systems, Inc. 221 USPQ 385 (Fed. Cir. 1984); In re Sun 31 USPQ 2d 1451 (CAFC 1993); Advanced Display Systems, Inc. v. Kent State University 54 USPQ 2d 1673 (CAFC 2000).

Further, the Examiner must identify wherein each and every facet of the claimed invention is disclosed in the applied reference. Ex Parte Levy 17 USPQ 2d 1461 (USPTO Board of Patent Appeals and Interferences 1990).

In addition, the Applicants submit that anticipation must meet strict standards and unless all of the same elements are found in exactly the same situation and united in the same way to form identical function in a single prior art reference, there is no anticipation. Tights, Inc. v. Acme-McCary Corporation, et al. 191 USPQ 305 (CAFC 1976).

Bearing in mind this criteria, the Applicants submit that although White discloses the use of perfluorocarbons for wounds, White does not disclose the element of an oxygen source serving for oxygenating blood and tissue, as presently claimed in independent claim 1 and in all depending claims.

In contrast, White explicitly excludes the oxygenation of the blood system, see column 5, lines 45-52, and claim 1.

The substantially fluorinated carbon material taught by White has an ability to transport oxygen. However, it is not a delivery source of oxygen as presently claimed.

In view of the fact that there is no teaching in White of a delivery source of oxygen, all the elements of the presently claimed invention are not taught nor suggested in White. Accordingly, a rejection of the claims under 35 USC 102(b) is not sustainable and the Applicants respectfully request the Examiner to withdraw this rejection.

Claims 1, 3, 22, and 24 have been rejected by the Examiner under 35 USC 102(b) as being anticipated by U.S. 6,110,483 to Whitbourne, et al. The Examiner states that Whitbourne, et al. teaches a substrate and an oxygen carrier wherein the carrier comprises a fluorocarbon compositions which are lipophilic of various polymer compositions.

Again, bearing in mind the hereinabove criteria set forth for finding anticipation under 35 USC 102, the Applicants submit that all the elements of the presently claimed invention are not present. In Whitbourne, et al., the fluorocarbon as described in column 1, line 16, is a coating material. In this case, the fluorocarbon forms a substrate which can be medicated (i.e., soaked or otherwise filled with the medical material).

In contrast, the present invention concerns the fluorocarbon as the oxygen carrier which is intended to be supported within a substrate. Again, since all of the elements in the presently claimed invention are not taught or suggested by the Whitbourne, et al. reference, a rejection under 35 USC

102(b) is not sustainable. The Applicants respectfully request the Examiner to withdraw the rejection of claims under 35 USC 102(b) on the basis of the Whitbourne, et al. reference.

The Applicants acknowledge their obligation under 37 CFR 1.56 to point out the inventor and inventor dates of each claim and that all of the claims are commonly owned by the inventors.

Claims 1, 3, 7-8, 14, 19-24, and 28 have been rejected by the Examiner under 35 USC 103(a) as being unpatentable over White in view of U.S. 6,146,358 to Rowe. In this rejection, the Examiner states that White teaches all of the limitations of the claims except for explicitly reciting a balloon substrate or polymer including pores having sizes and the range of 20-200 microns. The Examiner concludes it would have been obvious to one of ordinary skill in the art at the time of the invention to have utilized the composition as taught by White with the composition delivery device of Rowe for the well-known purpose of delivering the medical composition to a body surface as taught by White.

In response thereto, the Applicants point out that Rowe discloses a balloon catheter whereby a therapeutic agent with a carrier can be coated on the balloon. In this case, the carrier and therapeutic agent form the coating and no substrate is provided.

In contrast to the present invention, Rowe's disclosure and coating consist of a carrier and agent which is intended to be removed from the balloon at the site of treatment. The embodiment is described in claim 1 is further differentiated, whereby the agent is present in the form of microcapsules and

2869

affixed to the balloon by means of a mesh expandable stent. both cases, the disclosure of Rowe does not lead the present invention.

Specifically, the usage of a mesh stent does not imply the expert that a porous material with a predetermined pore size could be used.

Accordingly, the Applicants submit that the Examiner, in fact, has not made a prima facie case of obviousness on the basis of the White and Rowe references. Therefore, the Applicants respectfully request the Examiner to withdraw the rejection of the claims under 35 USC 103(b) on the basis of the White and Rowe references.

the arguments hereinabove set forth, submitted that each of the claims now in the Application define patentable subject matter not anticipated by the art of record and not obvious to one skilled in this field who is aware of references of record. Reconsideration and allowance are respectfully requested.

Respectfully submitted,

M. MILL

HEREBY CERTIFY THAT THIS CORRESPONDENCE IS Walter A. Hackler BEING DEPOSITED WITH THE U.S. POSTAL SERVICE

AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED Attorney of Record
TO: COMMISSIONER OF PATENTS, PO BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450, ON Registration No. 2:

REG. NO. 27, 792

MARCH

Registration No. 27,792

2372 S.E. Bristol Street, Suite B

WALTER A. HACKLER Newport Beach, California 92660

(949) 851-5010

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

arsons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork Reduction Act of 1995, no

Substitute for form PARAPETO RADE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known 2869 **Application Number JANUARY 3, 2002** Filing Date DR. CHRISTOPH HEHRLEIN et al. First Named Inventor 3736 Art Unit **Examiner Name** 2869 Attorney Docket Number

				U.S. PAT	ENT DOCUMENTS		
Examiner Initials		Cite No.1		Document Number  7  Number Kind Code (if known)	Publication Oate MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			US- 3,958,014	05-18-1976	WATANABE et al.		
<b>!</b>	<b>**</b>		US- 4,252,827	02-24-1981	YOKOYAMA et al.		
H			US- 4,445,500	05-01-1984	JEWELL L. OSTERHOLM		
П	1		US- 4,636,195	01-13-1987	HARVEY WOLINSKY		
Н			US- 4,795,423	01-03-1989	JEWELL L. OSTERHOM		
	寸		US- 4,909,252	03-20-1990	JEFFREY GOLDBERGER		
-+			US- 4,944,745	07-31-1990	SOGARD et al.		
	_		US- 5,059,166	10-22-1991	FISCHELL et al.	70	
H			US- 5,087,247	02-11-1992	HORN et al.	<u>3 -, ⇒</u>	
	一十		US- 5,199,939	04-06-1993	DAKE et al.		
			US- 5,951,458	09-14-1999	HASTINGS et al.	0 20	
			US- 6,048,332	04-11-2000	DUFFY et al.	3 = M	
~	<b>"</b>		US-				
Г			US-			1 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -	
Г			US-			10	
Г	$\neg$		US-			25	
Г			US-		<u> </u>		
$\Box$			US-			<del>                                     </del>	
			us-				
			US-		<b>\</b>		

					FOR	EIGN PATENT DO	CUMENTS		
Examiner Initials	Foreign Patent Document Cite Kinds		Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°			
MA			WO 97/32626			09-12-1997	Scimed Life Systems, Inc.		-
									╄
		1		_/					╂—
					Z				┼
									╁┈╴
					ļ				+
		$\downarrow \downarrow \downarrow$							+-
					_				1
		+		_		<del>/</del>			
			<del></del>	77		<u> </u>	_! <u></u>	1	

Considered Signature \*EXAMINER: Initiative reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner

**LOSMARY** 

Applicant's unique citation designation number (option-al). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

١,	MAR 2 8 2005	37	My Argaquired	App U.S. Patent and Trade lorespond to a collection of infor	PTO/SB/0 roved for use through 10/31/2002. OME mark Office: U.S. DEPARTMENT OF C nation unless it contains a valid OMB o	188 (10-01) 3 0851-0031 COMMERCE ontrol number.
	PADE	_	To do		mplete if Known	· · · ·
Substituti	a tor to <del>mination</del>		THE THE WAY	Application Number	2869	
INFC	RMATION	I DIS	SCLOSURE CE	Filing Date	JANUARY 3, 2002	
CTV.	TEMENT P	RV A	PPLICANT	First Named Inventor	DR. CHRISTOPH HEHRLEIN et	al.
SIA	I CHAICIAL C	,, ,	(I LIOAIII	Group Art Unit	3736	
	(use as many s	heets a	is necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2869	

xaminer nitials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2
M		MARKUS FERRARI et al. "CORONARY FLOW ANALYSIS DURING AUTOPERFUSION ANGIOPLASTY" CORONARY ARTERY DISEASE November/December 1997, Vol 8 No. 11/12, Pages 697-702 Rapid Science Publishers, USA	
W		WALTER A. TAN et al. "LONG-TERM CLINICAL OUTCOMES AFTER UNPROTECTED LEFT MAIN TRUNK PERCUTANEOUS REVASCULARIZATION IN 279 PATIENTS" Circulation, October 2, 2001, Pages 1609-1614, Vol. 104, USA	
		7	
		DO FIA	
		RECEIVED TAR 14 2092 3700 MAIL ROOM	
_,			
xamine Signatur		Date Considered 01/03/05	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

MAR 2 8 2015

p

PTC/SB/08a (06-03)

Approved for use through 07/31/2003 OMB 0651-0031
U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF CONVIENCE

Under the Peperwork Reduction and 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO TRADE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of

Complete if Known							
Application Number	10/038,468						
Filing Date	01/03/2002						
First Named Inventor	CHRISTOPH HEHRLEIN						
Art Unit	3736						
Examiner Name	UNKNOWN						
Attorney Docket Number	2869						

Officer					FAIT DOCUME	RITC			_
	Cite No.1	Document Number  Number Kind Code	Publication Date MM-DD-YYYY		PAT DOCUMENTS  Name of Patentee or  Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
سا		(if known) US- 4,366,169	12-28-1982		DAVID C. WH	ITE			
W			12-20-1702						
		US-	<del>  \                                   </del>						
		US-	<del>- \                                   </del>						
		US-	<del>                                     </del>						
		US-	<del>                                     </del>						
		US-	<del>                                     </del>						
		US-	<del> \</del>				REP	D. I.	
		US-	<del>                                     </del>				<del></del>	7.11	_
		US-	<del>\ \ \</del>				OCE .	1	_
		US-	<u> </u>	<b>\</b>			OCTQ	1 2003	_
		US-		<del>_</del>		<del></del>	7/10/0- 1	100	_
		US-					**PLUGY	CENTED DO	_
		US-						CENTER R3700	_
		US-			<u> </u>		$\rightarrow$		_
		US-			1		<del>-}+</del>		<u>-</u>
		US-				<u> </u>			_
		us-					<del></del>		
		US-					_ _/_		
		us-							_
		US-							<u>_</u>
			FOR	EIGN	PATENT DOC	UMENTS			
Examiner	Cite	Foreign Patent		Pu	blication Date	Name of Pate Applicant of Cited	entee or i Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	

فسنتا				FOR	EIGN PATENT DO	CUMENTS		
Examiner	Cite	Office <sup>3</sup>	Foreign Patent Document  Number Kind <sup>5</sup>		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
Initials'	No.	<u> </u>	0 372 088 A1	(if known)	06-13-1990	SUMITOMO ELECTRIC	Ì	$oxed{\Box}$
H		EP EP	0 112 658 A2		07-04-1984	CHILDREN'S HOSPITAL		1
7100								╄
							<u> </u>	╁
		<u> </u>						工
								_
							<u> </u>	+
			/	/ /	A X		ļ	╁╴
	L,	وا				<u> </u>	1	=
Exam			Wohal	ZM.	Maus	Date Considered	105/05	

Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds oddes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark

here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and this collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to by the USPTO. Time will vary depending upon the individual case. complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Any comments of the USPTO. Time will be sent to the Chief Information Any comments of the USPTO. Time will be sent to the Chief Information Any comments of the USPTO. Time will be sent to the Chief Information Any comments of the USPTO. Time will be sent to the USPTO. Time will